This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Racial gaps in the use of ERBB2-targeted therapy among older Medicare beneficiaries with breast cancer reduced significantly from 2010 to 2019, a new study finds.
Medscape Medical News